ReviewInternational journal of colorectal disease2026
The 'other' colonic polyposis syndromes-evolving insights and guidance for endoscopists.
Review in International journal of colorectal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePolyposis syndromes contribute to a significant proportion of colorectal cancer (CRC) diagnoses. While Lynch syndrome (LS) and familial adenomatous polyposis (FAP) are well characterised, a growing number of rarer polyposis syndromes are increasingly recognised in clinical practice. These conditions often present with overlapping phenotypes and variable penetrance, posing diagnostic and management challenges for the practising clinician. The evidence base remains limited, with current guidance largely derived from small cohort studies and expert opinion. This narrative review summarises the current literature on the genetic basis, clinical manifestations, and endoscopic features of the rarer colorectal polyposis syndromes, excluding LS and FAP.
methodsA comprehensive literature search was conducted using PubMed and Ovid databases. Selected articles were evaluated for relevance and quality, and key findings were synthesised narratively to provide an overview of current knowledge and emerging trends relating to the rarer polyposis syndromes.
resultsThis review consolidates international recommendations for surveillance and management, with a focus on practical guidance for the endoscopist. Advances in next-generation sequencing and multigene panel testing have reshaped our understanding of polyposis genetics, leading to the identification of several novel autosomal dominant and recessive syndromes. Despite these discoveries, surveillance protocols remain heterogeneous, and gaps persist in defining cancer risk, optimal timing of intervention, and the role of chemoprevention. Greater awareness of these syndromes among clinicians is essential for timely diagnosis and personalised management.
conclusionCollaborative registries, prospective data, and consensus-driven guidelines are urgently required to standardise care and improve outcomes for patients with rare polyposis syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.